Live from BIO 2010: Day three in review

Burrill: Focus on patients, not molecules
by Maureen Martino
The biopharma industry needs to focus less on molecules and more on patients. That was one of the key messages in Steven Burrill's annual state of the industry report presented at BIO earlier this week. Article

The future of pharma growth
by Maureen Martino
In his state of the industry talk, Steven Burrill outlined the steps biopharma companies are taking as they recognize that their biggest growth years are behind them. Sales growth has leveled off dramatically since the 1990s and organic growth is all but gone. Like other mature industries, Big Pharma expands its business now by acquiring smaller companies and laying off redundant employees. Read more...

FDA center directors discuss upcoming challenges
by Liz Jones
FDA Commissioner Margaret Hamburg was joined by acting CBER Director Karen Midthun and CDER Deputy Director Douglas Throckmorton in addressing some of the challenges currently facing the agency. Report

Biotech, Pharma are living in a fishbowl
by Maureen Martino
Biotech, pharma and medical device industries are facing unprecedented levels of scrutiny from Congress, individual states, medical societies, industry associations, and a whole host of other organizations that want to regulate industry interactions with physicians. Navigating those regulations was the topic of Living in the Fishbowl: Disclosure, Transparency and Compliance Issues at BIO 2010 on Wednesday. Story

A chat with Stempeutics
by Liz Jones
FierceBiotech sat down with BN Manohar, president of Stempeutics, which is headquartered in Bangalore and has R&D facilities in Malaysia and Manipal. The company is in the process of bringing the first stem cell therapy to the Asian market and is focusing on about eight products. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.